NCT07034677 Treatment With Indapamide in Patients With Post-Surgical Hypoparathyroidism
| NCT ID | NCT07034677 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Lars Rejnmark |
| Condition | Hypoparathyroidism Post-surgical |
| Study Type | INTERVENTIONAL |
| Enrollment | 24 participants |
| Start Date | 2025-08 |
| Primary Completion | 2025-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 24 participants in total. It began in 2025-08 with a primary completion date of 2025-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of this study is to investigate the effect of daily treatment with Indapamide for 14 days on urinary calcium excretion in patients with post surgical hypoparathyroidisme.
Eligibility Criteria
Inclusion Criteria: 1. Chronic post surgical hypoparathyroidism diagnosed \> 1 year ago 2. Age ≥ 18 years 3. Require treatment with active vitamin D ≥ 1 µg/day 4. Ionized plasma calcium between 1.15-1.25 mmol/L 5. 25(OH)D vitamin ≥ 50 nmol/L 6. Plasma magnesium \> 0.65 mmol/L 7. Able to read and understand Danish 8. Willing and able to sign the informed consent form Exclusion Criteria: 1. Estimated glomerular filtration rate (eGFR) \< 30 ml/min/1.73 m3 2. Active cancer or former (except thyroid and basal cell skin) cancer treatment \< 1 year ago 3. Pregnancy, pregnancy plans, or breastfeeding \< 1 year ago 4. Abnormal arterial pressure at time of screening defined as symptomatic hypotension or systolic blood pressure \< 100 mmHg 5. Plasma potassium \< 3.5 mmol/L 6. Any current disease that might affect the calcium metabolism such as but not limited to: 1. Recent prolonged immobility 2. Untreated diabetes (HbA1c \> 53 mmol/mol) 3. Severe liver disease or hepatic encephalopathy 4. Untreated thyroid disease 7. Current disease that might affect gastrointestinal absorption 8. Use of medications such as lithium or diuretics within 4 weeks prior to start of treatment 9. Known allergy or sensitivity to Indapamide, its excipients or sulfonamides 10. Known galactosemia, lactase deficiency, or glucose-galactose malabsorption
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07034677 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Hypoparathyroidism Post-surgical. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07034677 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT07034677 currently recruiting?
Yes, NCT07034677 is actively recruiting participants. Contact the research team at sarthorn@rm.dk for enrollment information.
Where is the NCT07034677 trial being conducted?
This trial is being conducted at Aarhus, Denmark.
Who is sponsoring the NCT07034677 clinical trial?
NCT07034677 is sponsored by Lars Rejnmark. The trial plans to enroll 24 participants.